Association of TP53 Mutations with Response to Anlotinib Treatment in Advanced Non-Small Cell Lung Cancer

Multitargeted antiangiogenic drugs have demonstrated significant antitumor activity against a variety of solid tumors. Anlotinib, a novel oral multitargeted antiangiogenic tyrosine kinase inhibitor, was approved as a third-line treatment for advanced NSCLC in China. However, predictive biomarkers ar...

Descripción completa

Detalles Bibliográficos
Autores principales: Fang, Shencun, Cheng, Wanwan, Zhang, Meiling, Yang, Rusong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Case Series
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7354100/
https://www.ncbi.nlm.nih.gov/pubmed/32753898
http://dx.doi.org/10.2147/OTT.S257052

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7354100/
https://www.ncbi.nlm.nih.gov/pubmed/32753898
http://dx.doi.org/10.2147/OTT.S257052

Ejemplares similares